Overview FT576 in Subjects With Multiple Myeloma Status: Recruiting Trial end date: 2040-02-01 Target enrollment: Participant gender: Summary This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage. Phase: Phase 1 Details Lead Sponsor: Fate TherapeuticsTreatments: Antibodies, MonoclonalCyclophosphamideDaratumumabFludarabine